Zoryve (roflumilast) is a cream and foam that's approved for treating certain skin conditions in adults and children. The 0.15% cream is used to treat eczema and the 0.3% cream is used to treat plaque psoriasis. The 0.3% foam is approved for seborrheic dermatitis. Zoryve (roflumilast) is a phosphodiesterase 4 (PDE4) inhibitor. It's thought to lessen inflammation on the skin by lowering the activity of a protein in the body called PDE4. Zoryve (roflumilast) is applied to the affected area(s) on the skin once a day. Side effects can include pain where you apply the medication and headache.
Mild-to-moderate eczema in people 6 years and older - 0.15% cream only
Plaque psoriasis in people 6 years and older - 0.3% cream only
Seborrheic dermatitis in people 9 years and older - 0.3% foam only
Zoryve (roflumilast) is a phosphodiesterase 4 (PDE4) inhibitor. It blocks a protein in the body called PDE4. This protein plays a role in causing inflammation in your body.
By blocking PDE4, Zoryve (roflumilast) lowers the protein's ability to cause inflammation. This is thought to help relieve signs and symptoms of plaque psoriasis, eczema, and seborrheic dermatitis.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Steroid-free topical medication
Only applied once a day, so it's convenient for most people
Generally safe to use for a long period of time
Few side effects
Not safe for people with moderate-to-severe liver conditions
Not approved for children under 6 years old with plaque psoriasis or eczema or for children under 9 years old with seborrheic dermatitis
No lower-cost generic available; brand-name medication only
For Zoryve (roflumilast) foam: Shake the can each time before you use it. Also, avoid placing the can near fire or lit cigarettes when you're applying the medication or right afterwards. The foam is flammable.
Only apply Zoryve (roflumilast) to skin that's dry. Rub it in completely until you no longer see it. This helps the medication get absorbed into your skin better.
Only apply Zoryve (roflumilast) onto the outside of your body (e.g., the skin). Never place it in your eyes, nose, mouth, vagina, or ears.
Try to apply Zoryve (roflumilast) around the same time every day. Pick a time that's easy for you to remember, such as before bedtime or first thing in the morning.
Wash your hands after you apply Zoryve (roflumilast), unless you need to use the medication to treat the skin condition on your hands. Washing your hands afterwards can help prevent you from getting the medication in your eyes or mouth.
Tell your prescriber or pharmacist about what medications you're taking or planning to take. These include prescription medications, over-the-counter products, and supplements. Your care team can check for possible drug interactions with Zoryve (roflumilast). For example, the levels of Zoryve (roflumilast) in the body can rise if you also take ketoconazole or erythromycin. This can raise your risk for side effects.
Discuss the risks and benefits of using Zoryve (roflumilast) with your prescriber if you're pregnant or breastfeeding. There isn't enough information to know whether it's safe for you or your baby.
If a healthcare professional says it's okay to use Zoryve (roflumilast) while you're breastfeeding, apply the medication to the smallest area of skin for the shortest time needed. Don't apply Zoryve (roflumilast) directly to the nipple area or any area of your skin that could touch your baby's skin.
Store Zoryve (roflumilast) at room temperature and keep it out of reach of children and pets.
Zoryve (roflumilast) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
The foam version of Zoryve (roflumilast) is flammable and it can catch on fire easily. Keep the foam can away from flames or lit cigarettes while you're applying Zoryve (roflumilast) and also right after you apply the medication onto your skin.
Apply a thin layer to the affected area(s) on the skin once daily and rub the medication in completely.
Moderate-to-severe liver problems
Mild-to-moderate eczema in people 6 years and older - 0.15% cream only
Plaque psoriasis in people 6 years and older - 0.3% cream only
Seborrheic dermatitis in people 9 years and older - 0.3% foam only
Moderate-to-severe eczema in adults and children ages 2 years and older
Plaque psoriasis - cream, ointment, foam
Scalp psoriasis - foam, solution
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Arcutis Biotherapeutics, Inc. (2023). Zoryve- roflumilast aerosol, foam [package insert]. DailyMed.
Arcutis Biotherapeutics, Inc. (2024). FDA approves Arcutis’ Zoryve® (roflumilast) cream 0.15% for the treatment of atopic dermatitis in adults and children down to 6 years of age. Globe Newswire.
Arcutis Biotherapeutics, Inc. (2024). Zoryve- roflumilast cream [package insert]. DailyMed.
Blauvelt, A., et al. (2024). Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial. Journal of the American Academy of Dermatology.
Draelos, Z. D., et al. (2023). Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: A post hoc analysis from a randomized controlled trial. British Journal of Dermatology.
Eichenfield, L., et al. (2023). Once-daily roflumilast cream 0.15% for atopic dermatitis: Pooled results: From INTEGUMENT 1/2 phase 3 trials. Annals of Allergy, Asthma & Immunology.
Lebwohl, M., et al. (2022). Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis. Journal of the American Medical Association.
Lebwohl, M., et al. (2023). Durability of efficacy and safety of roflumilast cream 0.3% in adults with chronic plaque psoriasis from a 52-week, phase 2 open-label safety trial. Skin.
Li, B. S., et al. (2019). Should we instruct patients to rub topical agents into skin? The evidence. The Journal of Dermatological Treatment.
Ludmann, P. (2022). Seborrheic dermatitis: Overview.
Milakovic, M., et al. (2021). Phosphodiesterase-4 inhibition in psoriasis. Psoriasis.
Stein Gold, L., et al. (2024). Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Journal of the American Academy of Dermatology.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.